Achaogen files European application for plazomicin; shares up 5% premarket

|About: Achaogen (AKAO)|By:, SA News Editor

Achaogen (NASDAQ:AKAO) is up 5% premarket on light volume on the heels of its announcement that is has submitted a marketing application in Europe seeking approval for plazomicin for the treatment of complicated tract infections, bloodstream infections due to certain Enterobacteriaceae and infections due to Enterobacteriaceae in adult patients with limited treatment options.

The FDA approved the antibiotic, branded as ZEMDRI, in June.

Subscribe for full text news in your inbox